Biotechnology in the US: Market Size, Businesses & Forecast 2026

The biotechnology industry in the United States encompasses establishments primarily engaged in performing research and experimental development in biological sciences, genomics, and cellular engineering to create medical, agricultural, and industrial products. According to the Biotechnology Innovation Organization (BIO), the broader national bioscience economy achieved an annual economic output of 3.2 trillion USD in 2023 (BIO/TEConomy 2024), demonstrating the sector's immense macroeconomic scale. The industry is currently moving toward advanced biomanufacturing, gene editing, and modernized clinical trials, backed by a STEM-intensive workforce that reached nearly 2.3 million employees acro

Industry snapshot

Key public data points

Historical & forecast

Get in touch and our analysts will be happy to help with custom market sizing, deeper segmentation, supplier detail or a bespoke study built for you.

What does the Biotechnology in the US industry cover?

The US biotechnology industry consists of entities focused on the scientific modification of living organisms or biological systems to develop commercial products and technologies. Under official federal classifications, this primary research domain spans genetic engineering, recombinant DNA technology, protein engineering, and advanced food or environmental biochemistry applications. The sector excludes standalone nanotechnology research but interfaces deeply with human therapeutics, agricultural enhancements, and clean-tech chemical processes.

• •Primary classification falls under NAICS code 541714, which explicitly covers Research and Development in Biotechnology (except Nanobiotechnology).
• •Scope includes medical biotechnology (biopharmaceuticals, diagnostics, vaccines), agricultural biotechnology (genetically modified crops, seed technologies), and industrial biotechnology (biofuels, industrial enzymes).
• •Activities cover laboratory research, preclinical studies, and experimental development phases prior to full-scale commercial manufacturing.

Who operates in the industry and how is it structured?

The domestic market structure is characterized by a bimodal division between a small tier of highly capitalized multinational developers and a vast network of agile startup laboratories. Industry participants are predominantly micro-to-medium-sized research labs that rely extensively on federal grants, venture capital, and licensing partnerships with major pharmaceutical manufacturers. These operators are concentrated within well-defined regional clusters that leverage local academic research institutions and specialized venture ecosystems.

• •The Small Business Administration (SBA) utilizes an employee size standard of 1,000 or fewer employees to define small business entities within NAICS code 541714.
• •Total nationwide operations reached approximately 150,000 business establishments by 2023, reflecting a robust entrepreneurial ecosystem.
• •Major geographic hubs include established biological clusters in Boston-Cambridge (Massachusetts), the San Francisco Bay Area (California), and San Diego (California).

What drives demand in the industry?

Demand for US biotechnology innovations is driven primarily by an aging demographic that requires novel therapeutic options for chronic and complex diseases. Agricultural challenges, such as climate-driven crop vulnerability and the need for higher yields, further boost the utilization of genetically modified organisms and gene-edited crops. Furthermore, ongoing federal investments via public health agencies provide a non-dilutive capital baseline that continuously stimulates early-stage discovery.

• •An increasing burden of chronic medical conditions like cancer and diabetes accelerates corporate demand for targeted cell and gene therapies.
• •The National Institutes of Health (NIH) acts as a structural catalyst, providing substantial public funding to academic and corporate labs to advance health sciences.
• •Global food supply chains demand higher-efficiency inputs, increasing the adoption of insect-resistant and herbicide-tolerant bioengineered seeds.

Who are the notable companies in the industry?

Competition in the US biotechnology market is intense and heavily reliant on intellectual property protection, speed-to-market, and regulatory execution. While emerging developers focus strictly on intellectual asset accumulation, mature public companies command deep pipelines and advanced biomanufacturing capacities. These large-scale operators utilize strategic mergers, acquisitions, and multi-billion-dollar licensing agreements to absorb innovative clinical assets from smaller research entities.

• •Amgen Inc. stands as one of the largest independent global biotechnology companies, maintaining vast therapeutic R&D operations inside the United States.
• •Biogen Inc. focuses heavily on neurological and neurodegenerative disease treatments, operating as a pillar of the domestic medical biotech sector.
• •Gilead Sciences Inc. commands a massive commercial and research presence, particularly within antiviral therapeutics, oncology, and cellular therapies.
• •Regeneron Pharmaceuticals Inc. utilizes proprietary mouse-modeling technologies to discover and manufacture fully human monoclonal antibody treatments.

What are the recent trends and outlook?

The industry is experiencing a transitional phase where rapid scientific breakthroughs in gene editing face a more disciplined private investment landscape. High-wage employment growth slowed to a measured 1.2% net gain in 2023 following a post-pandemic contraction in venture capital allocations from the historic highs of 2021. However, the long-term outlook remains strong due to the clinical validation of advanced modalities like mRNA vaccines, cellular therapeutics, and artificial-intelligence-driven drug discovery pipelines.

• •The average annual wage for a US bioscience worker reached more than 132,000 USD in 2023, outpacing the general private sector average by 83%.
• •Total domestic sector employment expanded by nearly 15% between 2019 and 2023, showcasing durable multi-year job growth despite macroeconomic headwinds.
• •Corporate strategy is shifting heavily toward localized biomanufacturing resilience and near-shoring production lines to protect clinical supply chains.

How is the industry regulated?

The US biotechnology sector operates under a rigid multi-agency regulatory structure known as the Coordinated Framework for Regulation of Biotechnology. Oversight responsibilities are divided based on the product's intended use, requiring developers to navigate extensive multi-year clinical testing, field trials, and environmental impact reviews. Recent federal policy directives have actively pushed these oversight bodies to modernize evaluation frameworks to accelerate biological innovation and domestic biomanufacturing capabilities.

• •The Food and Drug Administration (FDA) evaluates and approves biopharmaceuticals, human cell/tissue products, and the safety of bioengineered foods.
• •The US Department of Agriculture (USDA), specifically through APHIS, regulates the environmental safety and field testing of genetically engineered plants.
• •The Environmental Protection Agency (EPA) oversees environmental compliance and registers bioengineered microorganisms or plants expressing insecticidal properties.
• •Regulatory updates align with the federal Executive Order on Advancing Biotechnology and Biomanufacturing Innovation for a Sustainable, Safe, and Secure American Bioeconomy.

Government, statistical and trade sources used for this Claight analysis.

• Biotechnology Innovation Organization (BIO) / TEConomy Partners State Bioscience Economy Report 2024 ·
• US Small Business Administration (SBA) Table of Size Standards 2023 ·
• US Census Bureau North American Industry Classification System (NAICS) 2022 ·
• Congressional Research Service (CRS) Reports on Biotechnology Regulation 2024 ·
• White House Executive Order on Advancing Biotechnology and Biomanufacturing Innovation 2022